BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31625353)

  • 1. A Case of Lung Involvement in Peripheral T Cell Lymphoma.
    Li W; Zhang L; Huang X; Feng D; Zou X; Zhou Y
    Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.
    Advani RH; Hong F; Horning SJ; Kahl BS; Manola J; Swinnen LJ; Habermann TM; Ganjoo K
    Leuk Lymphoma; 2012 Apr; 53(4):718-20. PubMed ID: 21916830
    [No Abstract]   [Full Text] [Related]  

  • 3. Atypical presentation of a central nervous system aspergillosis in a peripheral T cell lymphoma patient.
    Larroquette M; Issa N; Gabriel F; Camou F
    Ann Hematol; 2020 Nov; 99(11):2711-2713. PubMed ID: 32681445
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
    Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
    Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary breast peripheral T-cell lymphoma not otherwise specified: report of a case.
    Muroya D; Toh U; Iwakuma N; Nakagawa S; Mishima M; Takahashi R; Takenaka M; Shirouzu K; Agaki Y
    Surg Today; 2015 Jan; 45(1):115-20. PubMed ID: 24395027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
    Zheng W; Zhu J; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
    Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
    Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
    Chihara D; Pro B; Loghavi S; Miranda RN; Medeiros LJ; Fanale MA; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Neelapu SS; Younes A; Fowler NH; Rodriguez MA; Wang M; Kwak LW; McLaughlin P; Dang NH; Oki Y
    Br J Haematol; 2015 Nov; 171(4):509-16. PubMed ID: 26260306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An unusual extranodal T-cell non-Hodgkin lymphoma.
    Coats JT; Mackie ADR; Kernohan NM; Ramkumar PG; McMahon LM; Goodlad JR; Tauro S
    Lancet; 2016 Sep; 388(10049):1127-1128. PubMed ID: 27628520
    [No Abstract]   [Full Text] [Related]  

  • 13. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
    Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
    Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
    Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral T-Cell Lymphoma Presenting as a Primary Uterine Cervix Mass: A Report of a Rare Case.
    Kosari F; Niknejad N; Nili F; Jahanbin B; Malek M
    Int J Gynecol Pathol; 2017 Nov; 36(6):523-527. PubMed ID: 28244895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related myelodysplastic syndrome in a case of cutaneous adult T-cell lymphoma.
    Fukuda N; Shinohara K; Ota I; Muraki K; Shimohakamada Y
    Int J Hematol; 2002 Jan; 75(1):67-71. PubMed ID: 11843294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.